Abstract 547P
Background
The association between acetaminophen exposure and 28-day mortality in critically ill patients with primary lung cancer is currently not well understood, with existing studies providing insufficient and inconclusive evidence. This study aims to explore the influence of variations in acetaminophen exposure on 28-day mortality among a cohort of critically ill patients with primary lung cancer.
Methods
Utilizing the Medical Information Market for Intensive Care (MIMIC)-IV v2.2 database, this cohort study involved 1,140 participants diagnosed as critically ill with primary lung cancer. Data collected included demographics (age, sex, race), comorbidities, severity scores (SOFA, APSIII, SAPSII, OASIS), vital signs, laboratory tests, and 28-Day Mortality. Cox regression analysis was applied to investigate the potential link between acetaminophen exposure and 28-day mortality.
Results
The incidence of overall 28-day mortality was 38% in non-acetaminophen exposure group and 21.9% in acetaminophen exposure group. Upon thorough model adjustment, 28-day mortality was significantly lower in the acetaminophen exposure group than in the non-acetaminophen exposure group [HR=0.69, 95% CI: 0.55–0.88, p=0.002]. Patients receiving acetaminophen demonstrated significant enhancements in all evaluated outcomes, notably ICU mortality, in-hospital mortality, 30-day mortality, 90-day mortality, and 365-day mortality, relative to those who were not treated with acetaminophen.
Conclusions
Acetaminophen administration is associated with a decreased 28-day mortality rate in critically ill patients with primary lung cancer. However, to establish causality, further randomized controlled trials are necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China No. 82302449.
Disclosure
All authors have declared no conflicts of interest.